The potent bisphosphonate ibandronate does not induce myeloma cell apoptosis in a murine model of established multiple myeloma.

The potent bisphosphonate ibandronate does not induce myeloma cell apoptosis in a murine model of established multiple myeloma.

Bisphosphonates are effective in the management of bone disease in patients with multiple myeloma and recent reports have suggested that they may also have an anti-tumour activity. In support of this, we have previously demonstrated that bisphosphonates can induce myeloma cell apoptosis in vitro; ho...

Πλήρης περιγραφή

Λεπτομέρειες βιβλιογραφικής εγγραφής
Κύριοι συγγραφείς:	Shipman, C, Vanderkerken, K, Rogers, M, Lippitt, J, Asosingh, K, Hughes, D, Van Camp, B, Russell, R, Croucher, P
Μορφή:	Journal article
Γλώσσα:	English
Έκδοση:	2000

Παρόμοια τεκμήρια

Bisphosphonates--mechanisms of action in multiple myeloma.
ανά: Shipman, C, κ.ά.
Έκδοση: (2000)

Bisphosphonates and osteoprotegerin as inhibitors of myeloma bone disease.
ανά: Croucher, P, κ.ά.
Έκδοση: (2003)

Bisphosphonates and in vivo models of multiple myeloma - Reply
ανά: Shipman, C, κ.ά.
Έκδοση: (2001)

Recombinant osteoprotegerin decreases tumor burden and increases survival in a murine model of multiple myeloma.
ανά: Vanderkerken, K, κ.ά.
Έκδοση: (2003)

Osteoprotegerin inhibits the development of osteolytic bone disease in multiple myeloma
ανά: Croucher, P, κ.ά.
Έκδοση: (2001)

Bisphosphonates induce apoptosis in human myeloma cell lines: a novel anti-tumour activity.
ανά: Shipman, C, κ.ά.
Έκδοση: (1997)

The bisphosphonate incadronate (YM175) causes apoptosis of human myeloma cells in vitro by inhibiting the mevalonate pathway.
ανά: Shipman, C, κ.ά.
Έκδοση: (1998)

Anti-tumour activity of bisphosphonates in human myeloma cells.
ανά: Shipman, C, κ.ά.
Έκδοση: (1998)

Osteoprotegerin (OPG) inhibits the development of osteolytic bone disease in the 5T2MM model of multiple myeloma.
ανά: Croucher, P, κ.ά.
Έκδοση: (2000)

Zoledronic acid inhibits the development of osteolytic bone disease and increases disease free survival in a murine model of multiple myeloma.
ανά: Croucher, P, κ.ά.
Έκδοση: (2001)

Osteoprotegerin and the development of myeloma bone disease
ανά: Croucher, P, κ.ά.
Έκδοση: (2004)

APOMINE (TM), a novel inhibitor of the meyalonate/isoprenoid pathway, promotes apoptosis of myeloma cells in vitro and is associated with a modulation of the myeloma disease in vivo.
ανά: Croucher, P, κ.ά.
Έκδοση: (2002)

Osteoprotegerin inhibits the development of osteolytic bone disease in multiple myeloma.
ανά: Croucher, P, κ.ά.
Έκδοση: (2001)

Zoledronic acid prevents the development of osteolytic bone disease and increases survival in a murine model of multiple myeloma
ανά: Croucher, P, κ.ά.
Έκδοση: (2002)

Myeloma cells isolated from patients with multiple myeloma express osteoprotegerin ligand.
ανά: Shipman, C, κ.ά.
Έκδοση: (2000)

Myeloma cells can down-regulate release of osteoprotegerin (OPG) from human bone cells - A contributing factor in myeloma bone loss?
ανά: Shipman, C, κ.ά.
Έκδοση: (2002)

Myeloma cells can promote osteoclastic activity rather than osteoclast recruitment in vitro; Evidence from the 5T2MM murine model of myeloma
ανά: Mueller, G, κ.ά.
Έκδοση: (2004)

5T2MM murine myeloma cells and CD138+ve human myeloma cells promote osteoclastic activity rather than osteoclast formation in vitro
ανά: Mueller, G, κ.ά.
Έκδοση: (2004)

Zoledronic acid prevents the development of myeloma bone disease and increases survival
ανά: Shipman, C, κ.ά.
Έκδοση: (2002)

Nitrogen-containing bisphosphonates induce apoptosis in human bone marrow-derived myeloma cells in vitro by inhibiting protein prenylation.
ανά: Gordon, S, κ.ά.
Έκδοση: (1999)

Apomine, an inhibitor of HMG-CoA-reductase, promotes apoptosis of myeloma cells in vitro and is associated with a modulation of myeloma in vivo.
ανά: Edwards, C, κ.ά.
Έκδοση: (2007)

Bone marrow endothelial cells produce osteoprotegerin: Evidence for a role in the development of myeloma bone disease
ανά: De Leenheer, E, κ.ά.
Έκδοση: (2004)

Tumour cells isolated from patients with multiple myeloma express the critical osteoclastogenic factor, RANKL.
ανά: Shipman, C, κ.ά.
Έκδοση: (2000)

Bone marrow endothelial cells express the osteoclastogenic factor RANKL and its decoy receptor OPG: Evidence for a role in the development of myeloma bone disease.
ανά: De Leenheer, E, κ.ά.
Έκδοση: (2002)

Zoledronic acid treatment of 5T2MM-bearing mice inhibits the development of myeloma bone disease: evidence for decreased osteolysis, tumor burden and angiogenesis, and increased survival.
ανά: Croucher, P, κ.ά.
Έκδοση: (2003)

Cells of the bone marrow microenvironment protect myeloma cells from apoptosis induced by TRAIL but not by agonists of TRAIL death receptors.
ανά: Locklin, R, κ.ά.
Έκδοση: (2005)

The bisphosphonate-ester apornine does not act by inhibiting protein prenylation, but enhances the effects of lovastatin on myeloma cells
ανά: Roelofs, A, κ.ά.
Έκδοση: (2006)

Gastrointestinal tolerability with ibandronate after previous weekly bisphosphonate treatment
ανά: Richard Derman, κ.ά.
Έκδοση: (2009-09-01)

Osteoblasts protect multiple myeloma cells from T-cell-induced apoptosis
ανά: Locklin, R, κ.ά.
Έκδοση: (2007)

The Effects of Forodesine in Murine and Human Multiple Myeloma Cells
ανά: Liesbeth Bieghs, κ.ά.
Έκδοση: (2010-01-01)

Osteoprotegerin (OPG) is a soluble decoy receptor for TRAIL/Apo2L and can inhibit TRAIL/Apo2L-induced apoptosis of human myeloma cells in vitro.
ανά: Shipman, C, κ.ά.
Έκδοση: (2002)

The Effectiveness of Zoledronic Acid and Ibandronic Acid in Delaying Skeletal-Related Events in Multiple Myeloma in Indonesia
ανά: Nutrisia Aquariushinta Sayuti, κ.ά.
Έκδοση: (2020-09-01)

Osteoprotegerin is a soluble decoy receptor for tumor necrosis factor-related apoptosis-inducing ligand/Apo2 ligand and can function as a paracrine survival factor for human myeloma cells.
ανά: Shipman, C, κ.ά.
Έκδοση: (2003)

Soluble rank ligand produced by myeloma cells causes generalised bone loss in multiple myeloma.
ανά: Clive Henry Buckle, κ.ά.
Έκδοση: (2012-01-01)

Administration of bisphosphonate (ibandronate) impedes molar tooth movement in rabbits: A radiographic assessment
ανά: V Venkataramana, κ.ά.
Έκδοση: (2014-01-01)

The bisphosphonate, zoledronic acid, induces apoptosis of breast cancer cells: evidence for synergy with paclitaxel.
ανά: Jagdev, S, κ.ά.
Έκδοση: (2001)

NE10790, a phosphonocarboxylate analogue of risedronate, induces human myeloma cell apoptosis in vitro
ανά: Roelofs, A, κ.ά.
Έκδοση: (2004)

Agonists of TRAIL death receptors induce myeloma cell apoptosis that is not prevented by cells of the bone marrow microenvironment.
ανά: Locklin, R, κ.ά.
Έκδοση: (2007)

P948: REAL-WORLD EVIDENCE OF BISPHOSPHONATES FOR MULTIPLE MYELOMA
ανά: Maria Nieves Lopez Muñoz, κ.ά.
Έκδοση: (2023-08-01)

Prevalence of bisphosphonate associated osteonecrosis of the jaws in multiple myeloma patients
ανά: Blum Christina, κ.ά.
Έκδοση: (2010-07-01)